“We continued to achieve multiple value-driving milestones during and since the end of the quarter. Last week, LYMPHIR was approved by the FDA for the treatment of a rare and incurable cancer. This is the first FDA-approved product in our portfolio and paves the way for Citius Oncology to transition from a development stage company to a commercial biopharmaceutical organization,” stated Leonard Mazur, CEO of Citius Pharma and Citius Oncology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
- Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
- TenX Keane addresses trading halt, continues toward combination closing
- Biotech Alert: Searches spiking for these stocks today
- Citius Pharmaceuticals announces FDA approval of Lymphir
Questions or Comments about the article? Write to editor@tipranks.com